{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/prescribing-information/loss-of-efficacy/","result":{"pageContext":{"chapter":{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy","depth":2,"htmlHeader":"<!-- begin field 3aa531ae-1fe8-45bd-b7cd-2ebb54e8fe26 --><h2>Loss of efficacy – a potential complication of drug treatment</h2><!-- end field 3aa531ae-1fe8-45bd-b7cd-2ebb54e8fe26 -->","summary":"","htmlStringContent":"<!-- begin item f54af001-e73d-4103-a931-196f1afb3e52 --><!-- begin field d6b43899-caef-4436-851c-6b186103f59b --><ul><li><strong>Loss of efficacy commonly occurs for all drugs in the long-term treatment of restless legs syndrome (RLS) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2013</a>]<strong>.</strong></li><li>Over time the drug dose often needs to be increased in order to maintain the original effect on symptoms. Unlike augmentation, symptoms are not worse than before treatment initiation. If loss of efficacy is suspected:<ul><li>Check for iron deficiency and/or whether serum ferritin is less than 50 to 75 micrograms/mL. Investigate causes for iron deficiency anaemia and offer oral iron supplements if appropriate.</li><li>For people taking monotherapy for RLS, rather than increasing the dose, consider adding in a second drug from another class. Alternatively, stop the current drug and switch to a drug in another class.</li></ul></li></ul><!-- end field d6b43899-caef-4436-851c-6b186103f59b --><!-- end item f54af001-e73d-4103-a931-196f1afb3e52 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}